Yonsei Med J.  2014 Mar;55(2):310-315.

Is High-Dose Leuprorelin Acetate Effective and Safe in Asian Men with Prostate Cancer? An Open-Label, Non-Comparative, Multi-Center Clinical Trial

• Lee SH
• Lee HM
• Kim SW
• Lee ES
• Hong SJ
• Kim CS
• Kang TW
• Chung BH

Abstract

PURPOSE
Leuprorelin is a well known luteinizing hormone releasing hormone agonist. However, there are insufficient data on the efficacy and safety of high dose leuprorelin acetate, especially in Asian patients with prostate cancer. We aimed to investigate the safety and efficacy of leuprorelin acetate 22.5 mg administered at three-month intervals in patients with prostate cancer.
MATERIALS AND METHODS
In an open, prospective clinical trial enrolling 47 patients, we aimed to assess the efficacy and safety of leuprorelin acetate 22.5 mg in treating patients with histologically confirmed prostate cancer. The primary objective of this study was to evaluate the efficacy of the leuprorelin acetate 22.5 mg in producing and maintaining castration levels of testosterone over a 6-month follow-up period and to determine its safety profile.
RESULTS
All 42 patients achieved serum testosterone levels within the castration range by 4 weeks. A breakthrough response was observed in one of 36 patients by 8 weeks. However, this patient was medically castrated by 12 weeks. There were no significant prostate-specific antigen (PSA) or testosterone changes according to clinical stage or body mass index. Twenty adverse events (AEs) in 15 of 42 patients (35.7%) were observed during this study. The most common AEs were hot flushes (n=4, 20.0%) with mild intensity, pain (n=2, 10.0%), and infection (n=2, 10.0%). No patient withdrew from the study due to AEs.
CONCLUSION
Leuprorelin acetate 22.5 mg was shown to be effective and safe in Asian patients with prostate cancer, even though sexual function decreased.

Keyword

Prostate cancer; luteinizing hormone releasing hormone agonist; adverse events

MeSH Terms

Asian Continental Ancestry Group*
Body Mass Index
Castration
Follow-Up Studies
Gonadotropin-Releasing Hormone
Humans
Leuprolide*
Male
Methods
Prospective Studies
Prostate*
Prostate-Specific Antigen
Prostatic Neoplasms*
Testosterone
Gonadotropin-Releasing Hormone
Leuprolide
Prostate-Specific Antigen
Testosterone

Reference

1. Statistics Korea. accessed on February 5, 2013. Available at: http://kostat.go.kr/portal/english/index.action.

2. Lee DH, Jung HB, Chung MS, Lee SH, Chung BH. The change of prostate cancer treatment in Korea: 5 year analysis of a single institution. Yonsei Med J. 2013; 54:87–91.

3. Cookson MM. Prostate cancer: screening and early detection. Cancer Control. 2001; 8:133–140.

4. Agarwal PK, Sadetsky N, Konety BR, Resnick MI, Carroll PR. Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes. Cancer. 2008; 112:307–314.

5. Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol. 2002; 168:9–12.

6. Tolis G, Ackman D, Stellos A, Mehta A, Labrie F, Fazekas AT, et al. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Proc Natl Acad Sci U S A. 1982; 79:1658–1662.

7. Chung KJ, Kim JJ, Lim SH, Kim TH, Han DH, Lee SW. Development and validation of the Korean version of expanded prostate cancer index composite: questionnaire assessing health-related quality of life after prostate cancer treatment. Korean J Urol. 2010; 51:601–612.

8. Chen J, Gefen A, Greenstein A, Matzkin H, Elad D. Predicting penile size during erection. Int J Impot Res. 2000; 12:328–333.

9. Chipkevitch E, Nishimura RT, Tu DG, Galea-Rojas M. Clinical measurement of testicular volume in adolescents: comparison of the reliability of 5 methods. J Urol. 1996; 156:2050–2053.

10. Berges R, Bello U. Effect of a new leuprorelin formulation on testosterone levels in patients with advanced prostate cancer. Curr Med Res Opin. 2006; 22:649–655.

11. Chu FM, Jayson M, Dineen MK, Perez R, Harkaway R, Tyler RC. A clinical study of 22.5 mg. La-2550: a new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol. 2002; 168:1199–1203.

12. Heyns CF, Simonin MP, Grosgurin P, Schall R, Porchet HC. South African Triptorelin Study Group. Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer. BJU Int. 2003; 92:226–231.

13. Damber JE, Tammela TL, Iversen P, Abrahamsson PA, Boccon-Gibod L, Olesen TK, et al. The effect of baseline testosterone on the efficacy of degarelix and leuprolide: further insights from a 12-month, comparative, phase III study in prostate cancer patients. Urology. 2012; 80:174–180.

14. Zagars GK, Pollack A, von Eschenbach AC. Serum testosterone--a significant determinant of metastatic relapse for irradiated localized prostate cancer. Urology. 1997; 49:327–334.

15. Smith MR. Obesity and sex steroids during gonadotropin-releasing hormone agonist treatment for prostate cancer. Clin Cancer Res. 2007; 13:241–245.

16. Oefelein MG, Cornum R. Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm. J Urol. 2000; 164(3 Pt 1):726–729.

17. Morote J, Esquena S, Abascal JM, Trilla E, Cecchini L, Raventós CX, et al. Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer. Urol Int. 2006; 77:135–138.

18. Wu AH, Whittemore AS, Kolonel LN, John EM, Gallagher RP, West DW, et al. Serum androgens and sex hormone-binding globulins in relation to lifestyle factors in older African-American, white, and Asian men in the United States and Canada. Cancer Epidemiol Biomarkers Prev. 1995; 4:735–741.

19. Pettaway CA. Racial differences in the androgen/androgen receptor pathway in prostate cancer. J Natl Med Assoc. 1999; 91:653–660.

20. You D, Jeong IG, Kim SW, Chung BH, Cho JS, Lee HM, et al. Impacts of leuprolide acetate on quality of life in patients with prostate cancer: a prospective multicenter study. Scand J Urol Nephrol. 2010; 44:399–405.